↓ Skip to main content

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Overview of attention for article published in Blood, August 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
10 tweeters

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
Published in
Blood, August 2018
DOI 10.1182/blood-2018-01-821629
Pubmed ID
Authors

Jorge E. Cortes, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

Abstract

This randomized, open-label, phase 2b study (NCT01565668) evaluated efficacy and safety of two dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML) who previously underwent transplant or one second-line salvage therapy. Patients (N=76) were randomized to 30- or 60-mg/day doses (escalations to 60 or 90 mg/day, respectively, permitted for lack/loss of response) of single-agent oral quizartinib dihydrochloride. Allelic frequency ≥10% was defined as FLT3-ITD mutated disease. Co-primary endpoints were composite complete remission (CRc) rates, and incidence of QT interval corrected by Fridericia's formula (QTcF) >480 msec (grade 2 or greater). Secondary endpoints included overall survival (OS), duration of CRc, bridge to transplant, and safety. CRc rates were 47% in both arms, similar to earlier reports with higher quizartinib doses. Incidence of QTcF >480 msec was 11% and 17% and QTcF >500 msec was 5% and 3% in 30-mg and 60-mg arms, respectively; less than earlier reports with higher doses of quizartinib. Median OS (20.9 and 27.3 weeks), duration of CRc (4.2 and 9.1 weeks), and bridge to transplant rates (32% and 42%) were higher in 60-mg arm than in 30-mg arm. Dose escalation occurred in 61% and 14% of patients in 30-mg and 60-mg arms, respectively. This high clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile. Need to dose-escalate more than half of patients who received quizartinib 30 mg also supports further investigation of treatment with quizartinib 60 mg/day.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 32%
Other 6 21%
Unspecified 4 14%
Student > Ph. D. Student 3 11%
Student > Doctoral Student 3 11%
Other 3 11%
Readers by discipline Count As %
Medicine and Dentistry 15 54%
Unspecified 6 21%
Pharmacology, Toxicology and Pharmaceutical Science 3 11%
Biochemistry, Genetics and Molecular Biology 2 7%
Agricultural and Biological Sciences 1 4%
Other 1 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2018.
All research outputs
#3,406,950
of 13,385,815 outputs
Outputs from Blood
#6,285
of 17,390 outputs
Outputs of similar age
#88,021
of 270,125 outputs
Outputs of similar age from Blood
#147
of 225 outputs
Altmetric has tracked 13,385,815 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 17,390 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,125 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.